Vertex Pharmaceuticals Incorporated (VRTX) stock is lower by -7.04% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives VRTX stock a score of 70 out of a possible 100.
That rank is mainly influenced by a long-term technical score of 83. VRTX's rank also includes a short-term technical score of 78. The fundamental score for VRTX is 48. In addition to the average rating from Wall Street analysts, VRTX stock has a mean target price of $259.89. This means analysts expect the stock to gain 15.86% over the next 12 months.
VRTX has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on VRTX!
Vertex Pharmaceuticals Incorporated (VRTX) stock has fallen -1.65% while the S&P 500 is lower by -2.5% as of 2:22 PM on Monday, Jan 24. VRTX is lower by -$3.76 from the previous closing price of $228.08 on volume of 1,553,451 shares. Over the past year the S&P 500 has risen 11.22% while VRTX is lower by -7.04%. VRTX earned $8.34 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 26.9.
Click Here to get the full Stock Report for Vertex Pharmaceuticals Incorporated stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
